Adcendo Benefits From ADC Excitement To Raise More Cash
Preclinical Biotech Brought In Over €80m
Executive Summary
The Danish start-up intends to use the proceeds from a €31m series A extension financing to initiate a broad clinical program for its uPARAP antibody-drug conjugate in sarcoma.
You may also be interested in...
Finance Watch: Gilde Closes Sixth Venture Fund With €740m For Drugs, MedTech
Private Company Edition: The €740m ($806.5m) Gilde Healthcare Venture&Growth VI Fund will back companies in Europe and North America. Among recent financings, VectorY raised a €129m ($138m) series A round, EyeBio expanded its series A to $130m and MBrace raised an $85m series B.
Finance Watch: New Funds Keep Venture Capital Flowing Into Biopharma
Private Company Edition: In the first week of April, Cure Ventures launched with a $350m fund, the Alzheimer’s Drug Discovery Fund received $200m for its venture philanthropy strategy and Canaan revealed $850m in new funds. Also, OnKure raised $53.7m and Phlow closed a $36m series B round.
BioNTech Gets In On ADC Action With DualityBio Licensing Deal
The German biotech is spending some of its pandemic capital on two antibody-drug conjugate candidates from the Chinese firm, including one in Phase II development.